Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis

doi:10.21203/rs.3.rs-792416/v1

Download PDF

Research

Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis

https://doi.org/10.21203/rs.3.rs-792416/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 24 Nov, 2021

Read the published version in Frontiers in Immunology →

Version 1

posted

You are reading this latest preprint version

Background: Epstein-Barr virus (EBV) is a common herpesvirus associated with malignant and non-malignant conditions. An accumulating body of evidence supports a role for EBV in the pathogenesis of multiple sclerosis (MS), a demyelinative disease of the CNS. However, little is known about the details of the link between EBV and MS. One obstacle which has hindered research in this area has been the lack of a suitable animal model recapitulating natural infection in humans. We have recently shown that healthy rabbits are susceptible to EBV infection, and viral persistence in these animals mimics latent infection in humans.

Methods: We used the rabbit model to investigate if peripheral EBV infection can lead to infection of the CNS and its potential consequences. We injected EBV intravenously in one group of animals, and PBS in another, with and without immunosuppression. Histopathological changes and viral dynamics were examined in peripheral blood, spleen, brain, and spinal cord, using a range of molecular and histopathology techniques.

Results: Our investigations uncovered important findings that could not be previously addressed. We showed that primary peripheral EBV infection can lead to the virus traversing the CNS. Cell associated, but not free virus in the plasma, correlated with CNS infection. The infected cells within the brain were found to be B-lymphocytes. Most notably, animals injected with EBV, but not PBS, developed inflammatory cellular aggregates in the CNS. The incidence of these aggregates increased in the immunosuppressed animals. The cellular aggregates contained compact clusters of macrophages surrounded by reactive astrocytes and dispersed B and T lymphocytes, but not myelinated nerve fibers. Moreover, studying EBV infection over a span of 28 days, revealed that the peak point for viral load in the periphery and CNS coincides with increased occurrence of cellular aggregates in the brain. Finally, peripheral EBV infection triggered temporal changes in the expression of latent viral transcripts and cytokines in the brain.

Conclusion: The present study provides the first direct in vivo evidence for the role of peripheral EBV infection in CNS pathology, and highlights a unique model to dissect viral mechanisms contributing to the development of MS.

Cellular & Molecular Neuroscience

Neurology

Immunology

EBV

Peripheral infection

Neuroinflammation

Demyelination

CNS infection

Multiple sclerosis

Rabbit Model

Epstein-Barr virus (EBV) is a B cell-tropic DNA virus belonging to the Herpesviridae family. The virus is often acquired early in childhood and then persists asymptomatically for life. EBV spreads from one host to another through virions intermittently shed in the saliva of infected hosts. The virus infects B lymphocytes via the interaction of the viral glycoprotein gp350/220 with the cell surface receptor, CD21 [1]. Latently infected cells, express a range of viral genes referred to as latency programs 0-III. Cells in latency III express 6 nuclear antigens (EBNAs), 3 latent membrane proteins (LMPs), a set of viral encoded miRNAs, and 2 non-coding RNAs (EBERs) [2]. EBERs are ubiquitously expressed in all forms of latency and are often used as targets for the detection of EBV in tissues. Collectively, latent viral proteins expressed during latency III appear to be fundamental for EBV transforming capacity [3]. In the face of a competent immune response, EBV shuts down the expression of all viral genes, with the exception of EBERs [4]. Despite the predominance of the latent cycle, EBV infected cells occasionally undergo acute lytic replication, which aids the dissemination of the virus. Moreover, the lytic cycle contributes to transient viremia, and increased peripheral viral load during the acute phase of infection [5].

Acquisition of EBV during late adolescence or early adulthood can lead to symptomatic infectious mononucleosis (IM) [6], which is an important risk factor for the development of multiple sclerosis (MS) [7]. MS is a disease that results in the destruction of myelin sheaths in the brain and spinal cord, a process known as demyelination. The influx of inflammatory immune cells and reactive gliosis are other important hallmarks of MS [8]. In addition to demyelination and inflammation, an accumulating body of evidence indicates the presence of EBV in MS [9–12]. However, it is unclear how peripheral EBV travels to the CNS and what its consequences are on the CNS.

The CNS is no longer considered an immune privileged site, as once thought. Rather, there is a bi-directional intricate communication between the periphery and the CNS. Inflammation in the periphery can interfere with the blood-brain barrier (BBB) integrity and induce changes in the brain [13, 14]. Similarly, when murine γ-herpesvirus 68 (MHV-68) is introduced directly into the brain of BALB/c mice, the virus can spread from the site of inoculation (i.e., brain) to the peripheral organs, including the spleen. Moreover, on reactivation of latent virus, MHV-68 can be readily detected in both the CNS and periphery [15].

Our laboratory has previously shown that intravenous inoculation of rabbits with EBV results in the virus establishing latency that mimics asymptomatic infection in humans [16]. Upon primary infection, rabbits elicited a strong humoral response, correlating with undetectable levels of the virus in peripheral blood. However, immunosuppression of latently infected animals using cyclosporin A (CsA), resulted in reactivation and marked increase in peripheral viral load. EBV reactivation was associated with the expression of the immediate early lytic marker, BZLF1, and a handful of latent viral genes. These animals also showed pronounced infiltration of infected cells into the liver and the spleen [16].

In this study, we aimed to understand the impact of peripheral EBV infection on the CNS in the rabbit model. We proposed that latent EBV infection in rabbits could promote pathological alterations in the CNS that may predispose the infected animals to features seen in MS, such as inflammation and demyelination.

Preparation of virus inoculum

B95-8, a B cell line of marmoset origin, was used to produce EBV for inoculation. The cells were grown in RPMI-1640 medium (GIBCO, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin-streptomycin solution (GIBCO, USA), 50 µg/ml gentamycin (Hyclone, USA), and 1× glutamine (GIBCO, USA) at 37℃, and 5% CO₂. Cells were then stressed by incubating at 30℃ for 24hr to stimulate lytic cycle and virus shedding into the supernatant. The supernatant was centrifuged, and subsequently passed through 0.2-µm nylon filter (Thermo Fisher, USA). The filtered supernatant was used for intravenous (IV) injections following quantification of EBV copy number using qPCR.

Animals and experimental design

This study was divided into 2 parts:

investigating viral spread from the periphery to the CNS
investigating the dynamics of EBV infection over time

Investigating viral spread from the periphery to the CNS

Four- to 8-week old New Zealand White (NZW) rabbits were obtained from a local supplier, and housed in our animal facility in the College of Medicine and Health Sciences (UAE University). Experiments were conducted on animals in adherence to the protocols approved by the Animal Research Ethics Committee of UAE University (Approval numbers: A-15-15; ERA-2018-5718). Following a 2-week acclimatization, a total of 24 rabbits were randomly allocated to four groups (Supplementary Fig. 1A):

Group 1 (EBV)

Eight animals were injected with 1×10⁷ EBV copies, as determined by qPCR, via the marginal ear vein.

Group 2 (PBS control)

Four animals were IV injected with PBS (volume equivalent to that of EBV inoculum).

Group 3 (EBV + CsA)

nine animals were injected with the same viral inoculum as for group 1 and treated with daily subcutaneous injections of cyclosporin A (CsA), (20mg/kg body weight, Sandimmune- Novaratis).

Group 4 (CsA control)

three animals were IV injected with PBS and immunosuppressed using daily CsA injections as in group 3.

Rabbits were monitored on a daily basis and sacrificed at day 14 post inoculation under Ketamine-Xylazine (40mg/kg and 5mg/kg, respectively) anesthesia. Whole blood was collected and separated into peripheral blood mononuclear cells (PBMCs) and plasma. Major organs including the spleen, brain and spinal cord were harvested.

Investigating the dynamics of EBV infection over time

In this set of experiments, NZW rabbits were divided into EBV group and PBS control group. At day 0, 15 animals in EBV group received the virus, and five animals in the control group received PBS via IV injection as described above. Three randomly selected rabbits from the EBV group and one rabbit from the control group were sacrificed at each of the following five time points: 3, 7, 14, 21 and 28 days post inoculation (Supplementary Fig. 1B). Whole blood, spleen, brain, and spinal cord were collected.

DNA extraction and qPCR for EBV genome

PBMCs and plasma were isolated from whole blood samples using density gradient centrifugation on Histopaque-1077 (Sigma, Poole, UK). Genomic DNA (gDNA) was extracted from PBMCs, plasma, and biopsied tissues from spleen, brain, and spinal cord using QIAamp DNA Mini and Blood Mini Kit (QIAGEN), according to manufacturer’s instructions.

Quantitative TaqMan PCR (Applied Biosystems) amplifying EBV BamHI fragment [17] was used to determine EBV copy number as previously described [18]. The amplification reactions were run in duplicates on an Applied Biosystem 7500 real time thermocycler (Applied Biosystems). gDNA extracted from Namalwa cells was used to create a standard curve. Samples with undetermined Ct values were interpreted to have zero copy number for the purpose of statistical analysis.

RNA extraction and RT-PCR

Total RNA was extracted from the brain using TRizol (Invitrogen, Germany). After determining the quantity and quality of the extract RNA using NanoDrop 2000c (Thermo), 1µg of DNase-treated RNA was reverse-transcribed to cDNA using the Reverse Transcription System (Promega). SYBR Green Real-time PCR was performed, using Applied Biosystems QuantStudio™ 7 Flex System, to determine the relative mRNA expression of tumor necrosis factor α (TNFα), interleukin-1β (IL1β), IL2, and IL6 [19]. The relative expression of latent EBV transcripts, EBER1, EBER2, EBNA1, and EBNA2 were also determined [20, 21]. Samples were run in duplicates, and experiments were repeated twice. Relative expression was determined using comparative CT (ΔΔCt) method. Rabbit-specific GAPDH (housekeeping gene), and non-infected PBS samples (experimental controls) were used as reference.

Histology, EBER in situ hybridization (EBER-ISH), immunohistochemistry, and immunofluorescence

Formalin-fixed, paraffin-embedded (FFPE) tissues were cut into 5-µm sections and stained with hematoxylin and eosin (H&E) for basic histological examination. To identify viral proteins and cell populations contributing to inflammation in the CNS, a number of primary antibodies for viral and cellular markers were used (Supplementary Table 1).

For EBER-ISH, tissues were hybridized with a combination of 2 digoxin end-labelled probes complementary to EBER1 and EBER2, as previously described [22]. Following blocking of the endogenous peroxidase activity, tissues were briefly digested with 0.1mg/ml proteinase K (Sigma). Sections were hybridized overnight with the probes, and two stringency washes were performed in 0.1×SSC buffer at 55°C. Mouse anti-digoxin antibody and Ultra-Sensitive ABC-Peroxidase Staining kit (Thermo Scientific, USA) were used for signal detection.

For chromogenic immunohistochemistry, heat-induced antigen retrieval was performed by incubating sections in boiling sodium citrate buffer (pH 6.2) for 10min. Endogenous peroxidase activity was quenched, followed by blocking in 5% BSA and 0.1% Triton-X 100 in 1×PBS for 1hr. Tissues were then incubated with primary antibodies at room temperature, overnight. Tissues were washed and incubated with appropriate secondary antibodies for 1hr. Diaminobenzidine (DAB) was used for signal detection and sections were counterstained with hematoxylin.

For immunofluorescence, sections were incubated with primary antibodies overnight. After washing, sections were incubated with fluorochrome-conjugated secondary antibodies for 1hr. Sections were washed, counterstained with DAPI and mounted using Fluoromount (Sigma). Fluorescence images were captured using fluorescence microscope (Zeiss).

For EBER-FISH and immunofluorescence, sections were hybridized overnight with EBER probes. After stringency wash, sections were incubated with goat anti-IgG for 1hr. Fluorochrome-conjugated anti-digoxin and anti-goat antibodies were used as secondary antibodies.

Protein extraction and ELISA

Homogenates of brain cortex were prepared in T-PER tissue protein extraction reagent (Thermo) and proteinase-inhibitor cocktail (Roche), using BeadBlaster™24 Homogenizer (Benchmark). Purified proteins were stored at -80°C until analysis. DuoSet ELISA development system for rabbit IL2 and IL6 were used according to the manufacturer’s instructions (R&D Systems). All samples were assayed in duplicates, and experiments were repeated 3 times. A standard curve was included in each experiment and used to determine the quantity of cytokines in the test samples.

Statistical analysis

Statistical analyses were performed using the GraphPad Prism Version 9.1.2 (GraphPad Software, San Diego, CA). Comparison between multiple groups was performed using one-way ANOVA or non-parametric multiple comparison, alpha = 0.05. Comparison between two groups was done using two-tailed unpaired t-test or nonparametric Mann-Whitney test. Data was displayed as mean ± SEM. Spearman or Pearson correlation was used to correlate between 2 variables. P value ≤ 0.05 was considered statistically significant.

Investigating viral spread from the periphery to the CNS

EBV inoculated rabbits exhibit viremia and high viral DNA load in the periphery

The presence of EBV in MS brain has been reported in several studies [9–11, 18]. Until now, the events that cause peripheral infection to reach the brain are poorly understood. In order to determine whether peripheral EBV infection on its own can lead to CNS infection, we injected EBV intravenously into eight healthy NZW rabbits. In healthy animals, antiviral T cell responses act as a barrier that limits systemic viral dissemination. Therefore, in another nine rabbits, we injected EBV and immunosuppressed them using CsA. This was implemented to overcome anti-EBV T cell responses and increase the likelihood of EBV spreading to the CNS in these animals.

In the eight animals inoculated with EBV, no disease manifestations were observed during the 14-day study period, or at autopsy. In the EBV + CsA group however, 1/9 rabbits showed changed temperament, decreased activity, and major loss in body weight. To minimize animal suffering, this rabbit was euthanized at day 7, as opposed to the scheduled day 14. At autopsy, the spleen was found to be significantly enlarged with macroscopic white nodules in 4/9 rabbits in the EBV + CsA group, but not in any of the eight animals in the EBV group.

EBV infection in the spleen was confirmed by EBER in situ hybridization (EBER-ISH) in all animals inoculated with the virus. No EBER signal was seen in the spleen of any of the control rabbits that were injected with either, PBS or CsA (Fig. 1A). This was further supported by the detection of the virus using qPCR. EBV genome was detected in the spleen of all the rabbits in both EBV and EBV + CsA groups (Fig. 1B). Thus, peripheral EBV infection was established in 100% of the animals inoculated with EBV, regardless of the immune status.

Since viremia is an important event in predisposing to CNS infection [23], we quantified EBV in the PBMCs and plasma. All the animals in the EBV group (8/8) and 8/9 animals in EBV + CsA group had quantifiable, but variable viral load in the PBMCs. None of the PBS/CsA controls had detectable virus. In the EBV + CsA group, the 1/9 animals which did not have detectable virus in the PBMCs, was the animal which was euthanized 1 week prematurely. This suggests that EBV detectability in peripheral blood may be suboptimal at 7dpi as opposed to 14dpi. As for plasma, 75% (6/8) of the animals in the EBV group and 78% (7/9) of EBV + CsA group were viremic (i.e., EBV DNA in plasma) (Fig. 1B). We also found significant correlation between the levels of viremia and splenic viral load in the EBV group, but not in the EBV + CsA group (Supplementary Fig. 2). This implies the interfering effects of immunosuppression on viremia levels. Among the 3 peripheral compartments (plasma, PBMCs and spleen), plasma had the lowest level of EBV DNA (Fig. 1B). This indicates that lytic shedding of the virus is relatively less frequent, and most of the virus is cell-associated.

Inflammatory cell aggregates develop in the CNS following peripheral EBV infection

To evaluate the impact of peripheral EBV infection on the CNS, we examined the brain and spinal cord for histopathological changes. Interestingly, we observed widespread presence of distinct cellular aggregates consisting of inflammatory cells and microglia nodules in the brain and spinal cord of (2/8) EBV and (7/9) EBV + CsA groups (Fig. 2). These aggregates were not observed in any of the PBS controls. However, 2/3 CsA controls developed similar CNS aggregates. These observations suggest that peripheral EBV infection can promote neuroinflammation in some hosts, depending on the host’s genetics and immune system. Immunosuppression can also lead to neuroinflammation, possibly as a result of reactivation of latent infection(s) other than EBV. We also noted that the cellular aggregates in the spinal cord were less in number and smaller in size than cerebral aggregates (Fig. 2). Moreover, the aggregates in the brain were widespread and present throughout the hemisphere, including the cerebrum, the meninges, and the cerebellum. Generally, these cellular aggregates were associated with CNS vasculature (Supplementary Fig. 3A). The aggregates were observed more frequently in the cerebrum than in the cerebellum. The aggregates also formed in both hemispheres (Supplementary Fig. 3B).

To determine the cellular makeup of the CNS aggregates, we immunostained sections of the brain and spinal cord for various cellular markers. CNS aggregates consisted of infiltrating macrophages (RAM11⁺), microglia (Iba1⁺), reactive astrocytes (GFAP⁺), and infiltrating B (CD21⁺) and T lymphocytes (CD3⁺), and neutrophils (Fig. 3A and Supplementary Fig. 4). Additionally, proliferating cells (PCNA⁺) and infiltrating lymphocytes, including CD8⁺ (but not CD4⁺), IgG⁺ (but not IgM⁺) and EBI2⁺ cells were dispersed within the aggregates (Fig. 3B). Notably, the majority of these infiltrating immune cells were also diffusely scattered in the CNS parenchyma and formed several small clusters of loosely connected cells that lacked macrophage aggregation. While blood-derived macrophages/microglia appeared to make up the center of most, if not all, CNS aggregates, astrocytes and scattered proliferating B cells were mainly associated with the outer part of the aggregates (Fig. 4A-B). Furthermore, to examine whether the presence of these aggregates is associated with demyelination, we stained for myelin basic protein (MBP). We observed disruption of myelin within the aggregates, but this did not extend beyond the aggregates (Fig. 4C and Supplementary Figs. 4 and 7B). Collectively, these observations suggest that peripheral EBV infection can lead to immune cells trafficking into the CNS, and the formation of cellular aggregates. The aggregates consist of proliferating B cells, T-cells, and astrocytes, with peripheral derived macrophages occupying the center. Notably, the aggregates appear to be completely devoid of myelinated nerve fibers.

EBV infected cells infiltrate the brain of both immunocompetent and immunosuppressed animals

Since EBV infection of the brain has previously been shown in MS cases [9–11, 22, 24–28], we wanted to know whether primary peripheral infection can lead to infection of the brain. We stained brain sections, from EBV and EBV + CsA groups and PBS/CsA controls, for EBERs. EBV was detected in the brain of 6/8 animals in the EBV group, and 9/9 in the EBV + CsA group, independent of the presence of cellular aggregates. EBV infected cells were not seen in any of the PBS/CsA controls (Fig. 5A). We also examined the distribution of transcriptionally active virus in the brain by staining a series of sections with anti-EBNA1. EBNA1⁺ cells were seen dispersed throughout the brain (Fig. 5B). Remarkably, massive infiltration of EBNA1⁺ cells took place in the granular layer of the cerebellum (Fig. 5B).

In humans, EBV is primarily carried by circulating IgD⁻ CD27⁺ isotype-switched memory B cells [29, 30]. To determine which cells are infected with EBV in the rabbit brain, we performed double staining for EBV (EBERs or EBNA2) and B-cells (IgM or IgG), in heavily infected brain sections. Both IgM⁺ and IgG⁺ cells were found to be EBV positive (Fig. 5C). These findings indicate that primary peripheral EBV infection can be a sufficient event for EBV infected B cells to infiltrate the CNS.

Investigating the dynamics of EBV infection over time

EBV load peaks at day 14 post infection in peripheral and CNS compartments

To evaluate infection dynamics and delineate changes in the incidence of CNS aggregates over time, we IV inoculated a new batch of rabbits with EBV and examined blood, spleen, brain, and spinal cord at five time points; 3, 7, 14, 21 and 28 days post infection (dpi).

In the peripheral compartment, EBV was detected in the PBMCs at all time points (Fig. 6). In the spleen, however, virus reached detectable levels by day 7 and remained detectable throughout the next 3 time points. Interestingly, EBV in the plasma (indicative of viremia) could not be detected until 14 and 21dpi. In the CNS, the virus was detected in the brain at 7, 14, 21 and 28dpi, and in the spinal cord at 7, 14 and 21dpi. Notably, all 3 animals (100%) sacrificed at day 14 exhibited detectable high virus load in the plasma, PBMCs, spleen and brain. Thus, day 14 was the optimal time point for virus detection in the periphery and CNS. Additionally, EBV DNA load increased significantly at day 14 in plasma, PBMCs, spleen and brain (Fig. 6).

To investigate if EBV level in the periphery is associated with CNS infection, we assessed the correlation of viral load in the spleen and blood with that in the CNS. EBV DNA load in the brain correlated significantly with both splenic and PBMCs viral load (Supplementary Fig. 5). However, EBV load in the spinal cord correlated only moderately with EBV levels in the plasma (viremia) (Supplementary Fig. 5). Thus, increased viral load, in the spleen and PBMCs, may be a determinant for virus infection of the brain. This also highlights the importance of cell-associated virus, rather than free virus, in EBV trafficking to the brain.

The occurrence of CNS aggregates peaks at days 14 and 21 of infection

We next examined coronal sections of the brain and cross sections of the spinal cord for the presence of inflammatory aggregates at 3, 7, 14, 21, and 28dpi. Although mild inflammation was frequently observed in the meninges and around blood vessels in the brain of infected animals, distinct cellular aggregates were only seen in the brain and spinal cord of animals sacrificed at days 14 and 21 (Fig. 7). Again, the aggregates in the spinal cord were smaller in size compared to the aggregates observed in the corresponding brain. Additionally, massive infiltration of the CNS by immune cells, including neutrophils, macrophages (Supplementary Fig. 6), and B and T lymphocytes (Supplementary Fig. 7) was observed at days 14 and 21 in sections with aggregates, but not in sections with limited mild inflammation. In agreement with part 1 of the study, the formation of aggregates was associated with disruption of MBP within aggregates, in both the brain (Supplementary Fig. 7) and spinal cord (Supplementary Fig. 8).

To determine if there was a difference in the number of cerebral aggregates at different time points, we cut 1000, 5µm sections from all 3 animals at each of the five time points. Aggregates were counted in sections at intervals of 50. Aggregates were observed to have great heterogeneity in morphology. Thus, for the purpose of counting, we defined an aggregate in the brain parenchyma as a clear continuous cluster of cells that is at least 60µm in diameter. The term aggregate also included any 2 cellular clusters that were connected by a thread of infiltrates. Thus, meningeal infiltrates, small vessels engorged with lymphocytes, clusters or perivascular cuffs that are less than 60µm in diameter were not counted. On average the number of aggregates reached the peak at 14 and 21dpi (Fig. 7B). We next compared peripheral and CNS viral load in animals that developed CNS aggregates and those without aggregates. We found that animals with aggregates had significantly elevated levels of EBV DNA in PBMCs compared to animals without aggregates (Fig. 7C). This reflects a link between the level of cell-associated virus, but not cell-free virus, in the peripheral blood and the occurrence of CNS cellular aggregates. Thus, viremia may not be a determinant for the development of these structures in the CNS.

Peripheral EBV infection results in altered expression of cytokines and latent viral transcripts in the brain

To understand whether peripheral EBV infection is associated with changes in cytokine expression in the brain, and hence aggregate formation, we performed qPCR for tumor necrosis factor α (TNFα), interleukin-1β (IL1β), interleukin-2 (IL2) and interleukin-6 (IL6). Analysis of relative expression over the 5 time points of infection revealed significant upregulation of TNFα, IL1β and IL2 at 28dpi, compared to the brain of non-infected PBS controls (Fig. 8A). IL2 and IL6, on the other hand, were significantly upregulated as early as 14dpi (Fig. 8A). Furthermore, we determined whether the upregulation of these cytokines in the brain was coupled with altered expression of EBV latent transcripts. The expression of EBER1, EBER2 and EBNA1, but not EBNA2 was significantly elevated at day 28 (Fig. 8B). EBER2 was also significantly upregulated at day 14.

When analysis was limited to animals that developed CNS aggregates, the expression of IL2 and IL6 was significantly elevated at 14dpi. Day 14 was also the peak point for the expression of TNFα and IL1β, but the difference was not significant (Supplementary Fig. 9A). Comparison of viral transcripts in animals positive for brain aggregates, revealed significantly elevated expression of EBER2 and EBNA1 at 14dpi (Supplementary Fig. 9B).

Heat map of Spearman correlation of viral transcripts and cytokine expression in the brain of infected animals, indicated a positive correlation between EBER1/2 and the cytokines IL6, IL2 and IL1β, (Supplementary Fig. 9C). Together, these results imply that increased mRNA expression of latent EBV transcripts is accompanied by increased expression of inflammatory and regulatory cytokines in the brain.

We also examined the impact of EBV infection on the protein levels of IL2 and IL6 in the brain. IL6 level was found to be significantly high at 21dpi, a time point at which aggregate occurrence also peaked (Fig. 8C). Interestingly, there was a significant drop in the regulatory IL2 level at day 7 (Fig. 8C), the time point that preceded aggregate formation. These observations suggest that the increased production of inflammatory IL6 (21dpi) was not counteracted by production of regulatory IL2 in the brain.

Previous reports have frequently demonstrated the presence of EBV in the brain of MS patients, implicating a role for the virus in the pathogenesis of this disease [9, 11, 22]. However, the dynamics of virus trafficking to the brain, and its subsequent impact on disease development and/ or progression, are poorly understood. Addressing these questions has been challenging due to the lack of a suitable animal model of EBV infection. We and others have recently shown that rabbits are susceptible to EBV, and the infection mimics that observed in humans [16, 31–33]. Using the rabbit model, we explored the neuropathogenic potential of primary peripheral EBV infection. The findings uncovered several novel aspects of the dynamics of EBV infection in the periphery and CNS. 1) Intravenous inoculation of the virus resulted in widespread infection in all three peripheral compartments examined: spleen, PBMCs, and plasma. 2) Peripheral infection resulted in the virus traversing the brain. 3) Infection in the brain correlated with cell-associated virus, rather than circulating free virus in the plasma. 4) Peripheral EBV infection induced the formation of inflammatory cellular aggregates in the CNS, and these aggregates were composed of blood-derived macrophages and surrounded by reactive astrocytes and infiltrating B and T lymphocytes.

Primary EBV infection during late adolescence can cause symptomatic infectious mononucleosis (IM). Both symptomatic and asymptomatic primary infection cause high viral load in the periphery. However, disrupted immunological profile is rather unique to IM [34–36]. This emphasizes that EBV associated diseases emerge as a result of changes in the immune components triggered by the infection. In this study, we investigated primary EBV infection in healthy rabbits, and rabbits immunosuppressed with CsA. High viral load was detected in the peripheral compartments of all animals, particularly the immunosuppressed (EBV + CsA) group. This group also exhibited more than 10-fold higher levels of free virus in the plasma. However, the level of free virus did not correlate with brain infection. By contrast, there was a positive correlation between infected cells in the PBMCs and spleen, and brain infection. These findings support the idea that CNS infection is ascribed to migrating infected lymphocytes, most probably B cells.

Immune cell aggregation developed in rabbit brains without overt signs of neurological deficits. Similarly, it has been reported that intranasal infection of 129/SvEv mice with rabies CVS-F3 does not result in neurological manifestations, despite the occurrence of neuroinflammation, BBB breakdown and the increased expression of the proinflammatory cytokines such as IL6 and TNFα [37]. Importantly, cell aggregates formed only in some animals. Why only a fraction of infected animals developed CNS aggregates remain to be explored. However, our results suggest that EBV load in PBMCs may partly be linked to the formation of these structures. Additionally, host factors such as genetic background and the fitness of immune system to control viral infection are also likely to be important. Cell aggregation also developed in some immunosuppressed non-infected rabbits, and this may be due to reactivation of endogenous opportunistic pathogens in rabbits.

Cell aggregates in the CNS of rabbits contained a heterogeneous cell population made up of brain resident cells, infiltrating macrophages, neutrophils and B and T lymphocytes. In general, aggregates were seen at dissimilar stages of evolution in a given section, and thus differed in composition. Most of the aggregates had infiltrating macrophages as the prominent core surrounded by reactive astrocytes and dispersed lymphocytes. However, few aggregates lacked macrophage infiltration, but contained either a cluster of reactive glia or loosely connected lymphocytes. Brain-infiltrating T lymphocytes were mainly CD8⁺ cells, while B lymphocytes expressed proliferation marker PCNA, IgM, IgG and EBI2. Notably, EBI2 has been reported to be upregulated in activated T and B lymphocytes, and affects the movement of these cells [38–41]. EBI2 expression by astrocytes was shown to promote the migration of macrophages [42].

Immune aggregates reminiscent of organized lymphoid structures were previously recognized in the meninges of MS brain, and have gained attention as potential pathogenic feature of the disease [43, 44]. In addition to MS, EBV infection has been associated with the formation and/or persistence of these immune aggregates (also known as ectopic lymphoid-like structures) in the inflamed tissue in certain organ-specific autoimmune diseases [9, 45–47]. The ectopic lymphoid-like structures observed in meningeal inflammation in MS contained distinct clusters of CD20⁺ B cells and CD138⁺ plasma cells, intermingled with CD35⁺ follicular dendritic cells and CD3⁺ T cells [48]. These structures expressed markers that determine the fate of B cells including CXCL13, CD27, and BAFF [26, 49]. In spite of the spatial association of B lymphocyte with the aggregates, the phenotypes observed in cell aggregates in the rabbit’s CNS did not mimic those observed in MS ectopic lymphoid-like structures. Moreover, the cellular aggregates observed in the rabbit CNS were entirely devoid of myelinated nerve fibers, suggesting that some form of demyelination was occurring within these aggregates. However, the underlying mechanisms for this demyelination remain to be further investigated.

We also showed that the frequency of detecting EBV infection and viral load reached the peak at day 14, and this coincided with the peak of aggregate formation. However, the viral load in the CNS did not differ between animals that developed aggregates and those that did not [50]. In agreement with our results, the load of Theiler's Murine Encephalomyelitis Virus (TMEV) in the CNS of susceptible or resistant mice strains to EAE has been shown not to correlate with disease development. Instead, disease outcome correlated well with immune response to viral components. Thus, virus trafficking into the CNS is not sufficient for the neuropathological changes to occur.

Another important finding from our rabbit model is the positive correlation between increased expression of viral latent transcripts, particularly the ubiquitously expressed EBERs and the inflammatory cytokines IL1β and IL6, and the regulatory cytokine IL2 in the brain. On similar grounds, induction of experimental autoimmune encephalitis (EAE) followed by infection with murine γ-herpesvirus 68 (MHV-68), a virus that naturally infects rodents and is biologically similar to EBV, was shown to result in aggravated EAE in mice [51]. The latent infection in mice was found to cause increased T lymphocyte infiltration into the CNS, and suppress the anti-inflammatory phenotype of T cells; regulatory T cells, both in the periphery and CNS [51].

We also observed a positive correlation between the expression of EBNA1 and EBNA2 and TNFα expression in the brain. A recent study reported that immunizing mice with EBNA1 amino acid region 411–426 led to neurological deficits reminiscent of EAE, and the development of MRI-confirmed cortical lesions [52]. This region of EBNA1 was also found to trigger high antibody response in individuals with relapsing-remitting and secondary progressive MS, and these antibodies cross-reacted with MBP amino acid region 205–224 [52]. Furthermore, EBV latent proteins were found to be upregulated in MS lesions [28]. Virus reactivation in the MS brain was also associated with marked neuroinflammation and demyelination leading to fatal immune reconstitution inflammatory syndrome [53, 54]. Our study and these reports support the hypothesis that transcriptionally active EBV in the brain promotes immunological alterations.

Additionally, we demonstrated elevated mRNA levels of IL1β and TNFα at the later stage of infection (28dpi). These Th1 cytokines (IL1β, TNFα, IFNγ) were implicated in impaired BBB [37, 55–58]. It has been suggested that virus infection of the CNS incites the generation of inflammatory cytokines, which in return compromises the integrity of BBB, for example by altering the expression of BBB tight junction proteins [59–62]. Thus, BBB breakdown could be a consequence of viral infection of the CNS [59, 61, 63]. One could argue that increased mRNA levels of IL1β, TNFα at 28dpi may be followed by increased BBB permeability and recurrent influx of immune cells into the CNS. Whether EBV infection disrupts BBB integrity warrants further investigation.

Another critical issue arising from this study is the need to determine antigen specificity of lymphoid infiltrates in the CNS. The functional characterization of virus-specific immune response could further explain the inflammatory response and identify the extent of the damage brought about by either virus infected cells or immune response directed against transcriptionally active virus [64]. It has been shown that EBV-specific CD8⁺ T cells make up ~ 0.5–2.5% of total brain-infiltrating CD8⁺ T cells in MS [65]. This frequency was found to be significantly higher than CD8⁺ T cells reactive against MBP, CMV, or influenza virus. Further characterization of EBV-specific CD8⁺ T cells showed the expression of degranulation marker CD107a, perforin, and granzyme B, indicating their cytotoxic nature [65].

In conclusion, our results support a neuropathogenic potential of EBV. The neuroinflammation and immunopathological aspects of EBV gleaned from the rabbit model will help us explore, otherwise poorly understood, viral-host interactions that can be essential for the pathogenesis of EBV-associated neuropathologies including MS. The flexibility of this model offers avenues to examine the CNS-periphery axis during viral infection, and to identify potential cofactors for EBV-associated neuropathology. Further studies are needed to determine the cellular behavior and events that are crucial in the formation of neuroinflammatory aggregates, the resulting tissue damage, and the resolution of inflammation. Studying this cascade of events can provide us with an opportunity to critically evaluate potential and specific therapeutic targets that are essential to either halt the progression of EBV-associated neuropathologies or promote resolution of neuroinflammation.

BBB: blood-brain barrier; CMV: cytomegalovirus; CsA: Cyclosporin A; DAB: Diaminobenzidine; EAE: experimental autoimmune encephalitis; EBERs: Epstein-Barr virus-encoded RNAs; EBI2: Epstein-Barr virus induced gene 2; EBNA: Epstein-Barr nuclear antigens; EBV: Epstein-Barr virus; FBS: Fetal bovine serum; FFPE: Formalin-fixed paraffin-embedded; gDNA: Genomic DNA; GFAP: Glial fibrillary acidic protein; H&E: Hematoxylin and eosin; Iba1: Ionized calcium binding adaptor molecule 1; IFNγ: interferon gamma; IL: interleukin; IM: Infectious mononucleosis; IV: Intravenous; LMPs: latent membrane proteins; MBP: Myelin basic protein; MHV-68: Murine herpesvirus 68; NZW: New Zealand White; PBMCs: peripheral blood mononuclear cells; RAM11: rabbit-specific macrophages; TNFα: tumor necrosis factor alpha; TMEV: Theiler’s murine encephalomyelitis virus; Tregs: regulatory T cells

Acknowledgements

We would like to thank Dr. Mahmoud H Ali for monitoring the rabbits and advise on their care. We would also like to thank the staff of Tawam Hospital Pharmacy for their support in acquiring the cyclosporin A.

Authors’ contributions

Study conception and design was performed by GK. AS and NR performed animal experiments, sample collection, and data analysis and interpretation. SS provided technical guidance on histopathology examination, immunohistochemistry and immunofluorescence staining. AS and GK drafted the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by UAEU Zayed Centre-Based grants 31R135 and 31R259.

Availability of data and materials

Data are available upon reasonable request.

Ethics approval and consent to participate

All animal procedures were reviewed and approved by the Institutional Review Board, and experiments were conducted in adherence to the protocols approved by the Animal Research Ethics Committee of UAE University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Vrzalikova K, Sunmonu T, Reynolds G, Murray P. Contribution of Epstein⁻Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma. Pathogens. 2018 Jun 27;7(3).
Long HM, Meckiff BJ, Taylor GS. The T-cell Response to Epstein-Barr Virus-New Tricks From an Old Dog. Front Immunol. 2019;10:2193.
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821.
Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front Oncol. 2018 Jun 13;8(211).
Antsiferova O, Müller A, Rämer PC, Chijioke O, Chatterjee B, Raykova A, Planas R, Sospedra M, Shumilov A, Tsai M-H, Delecluse H-J, Münz C. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog. 2014 Aug;10(8):e1004333.
Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92.
Hedström AK, Huang J, Michel A, Butt J, Brenner N, Hillert J, Waterboer T, Kockum I, Olsson T, Alfredsson L. High Levels of Epstein-Barr Virus Nuclear Antigen-1-Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk. Front Neurol. 2019;10:1368.
Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, Magliozzi R, Allen I, McDonnell G, Kee R, Naughton M, Fitzgerald DC, Reynolds R, Neal JW, Howell OW. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol. 2018;84(6):829–42.
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 26;204(12):2899–912.
Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, Sefia E, Meager A, Elia A, Middeldorp JM, Clemens M, Farrell PJ, Giovannoni G, Meier U-C. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012 Jan 3;78(1):15–23.
Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH. Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm. 2018 Jul;5(4):e466.
Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM, NeuroproMiSe EBV Working Group. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011 Sep;134(Pt 9):2772–86.
Liu Y, Zhang S, Li X, Liu E, Wang X, Zhou Q, Ye J, Wang J-Z. Peripheral inflammation promotes brain tau transmission via disrupting blood-brain barrier. Biosci Rep. 2020 Feb 28;40(2).
Furutama D, Matsuda S, Yamawaki Y, Hatano S, Okanobu A, Memida T, Oue H, Fujita T, Ouhara K, Kajiya M, Mizuno N, Kanematsu T, Tsuga K, Kurihara H. IL-6 Induced by Periodontal Inflammation Causes Neuroinflammation and Disrupts the Blood-Brain Barrier. Brain Sci. 2020 Sep 27;10(10).
Kang H-R, Cho H-J, Kim S, Song IH, Lee TS, Hwang S, Sun R, Song MJ. Persistent infection of a gammaherpesvirus in the central nervous system. Virology. 2012 Feb 5;423(1):23–9.
Khan G, Ahmed W, Philip PS, Ali MH, Adem A. Healthy rabbits are susceptible to Epstein-Barr virus infection and infected cells proliferate in immunosuppressed animals. Virol J. 2015 Feb 18;12:28.
Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr Virus Quantitation by Real-Time PCR Targeting Multiple Gene Segments: A Novel Approach to Screen for the Virus in Paraffin-Embedded Tissue and Plasma. The Journal of Molecular Diagnostics. 2004 Nov 1;6(4):378–85.
Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLOS ONE. 2018 Feb 2;13(2):e0192109.
Schnupf P, Sansonetti PJ. Quantitative RT-PCR profiling of the Rabbit Immune Response: Assessment of Acute Shigella flexneri Infection. PLOS ONE. 2012 Jun 4;7(6):e36446.
Wang C, Wang H, Zhang Y, Guo W, Long C, Wang J, Liu L, Sun X. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism. Oncol Rep. 2017 Apr;37(4):2109–20.
Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M. Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA. Virology. 2015 Jan 1;474:117–30.
Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13(2):e0192109.
Archibald LK, Quisling RG. Central Nervous System Infections. Textbook of Neurointensive Care. 2013 May 7;427–517.
Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. J Virol. 2019 15;93(24):e00980-19.
Angelini DF, Serafini B, Piras E, Severa M, Coccia EM, Rosicarelli B, Ruggieri S, Gasperini C, Buttari F, Centonze D, Mechelli R, Salvetti M, Borsellino G, Aloisi F, Battistini L. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9(4):e1003220.
Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, Chiappetta G, Magliozzi R, Reynolds R, Coccia EM, Aloisi F. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010 Jul;69(7):677–93.
Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R, Aloisi F. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013 Jan;72(1):29–41.
Veroni C, Serafini B, Rosicarelli B, Fagnani C, Aloisi F. Transcriptional profile and Epstein-Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J Neuroinflammation. 2018 Jan 16;15(1):18.
Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol. 2000 Sep 15;165(6):2975–81.
Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol. 2004 May;78(10):5194–204.
Osborne AJ, Atkins HM, Balogh KK, Brendle SA, Shearer DA, Hu J, Sample CE, Christensen ND. Antibody-Mediated Immune Subset Depletion Modulates the Immune Response in a Rabbit (Oryctolagus cuniculus) Model of Epstein-Barr Virus Infection. Comp Med. 2020 Oct 1;70(5):312–22.
Okuno K, Takashima K, Kanai K, Ohashi M, Hyuga R, Sugihara H, Kuwamoto S, Kato M, Sano H, Sairenji T, Kanzaki S, Hayashi K. Epstein-Barr virus can infect rabbits by the intranasal or peroral route: an animal model for natural primary EBV infection in humans. J Med Virol. 2010 May;82(6):977–86.
Kanai K, Takashima K, Okuno K, Kato K, Sano H, Kuwamoto S, Higaki H, Nagata K, Sugihara H, Kato M, Murakami I, Hayashi K. Lifelong persistent EBV infection of rabbits with EBER1-positive lymphocyte infiltration and mild sublethal hemophagocytosis. Virus Research. 2010 Oct 1;153(1):172–8.
Abbott RJ, Pachnio A, Pedroza-Pacheco I, Leese AM, Begum J, Long HM, Croom-Carter D, Stacey A, Moss PAH, Hislop AD, Borrow P, Rickinson AB, Bell AI. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. J Virol. 2017 Oct 13;91(21):e00382-17.
Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, Ploutz-Snyder R, Rochford R. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis. 2012 Mar 15;205(6):906–13.
Dunmire SK, Grimm JM, Schmeling DO, Jr HHB, Hogquist KA. The Incubation Period of Primary Epstein-Barr Virus Infection: Viral Dynamics and Immunologic Events. PLOS Pathogens. 2015 Dec 1;11(12):e1005286.
Phares TW, Kean RB, Mikheeva T, Hooper DC. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J Immunol. 2006 Jun 15;176(12):7666–75.
Clottu AS, Mathias A, Sailer AW, Schluep M, Seebach JD, Pasquier RD, Pot C. EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis. Cell Reports. 2017 Jan 3;18(1):213–24.
Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. Nature. 2009 Aug 27;460(7259):1122–6.
Gatto D, Paus D, Basten A, Mackay CR, Brink R. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity. 2009 Aug 21;31(2):259–69.
Kelly LM, Pereira JP, Yi T, Xu Y, Cyster JG. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and non-lymphoid tissues. J Immunol. 2011 Sep 15;187(6):3026–32.
Rutkowska A, O’Sullivan SA, Christen I, Zhang J, Sailer AW, Dev KK. The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages. Sci Rep. 2016 May 11;6(1):25520.
Mitsdoerffer M, Peters A. Tertiary Lymphoid Organs in Central Nervous System Autoimmunity. Front Immunol. 2016;7:451.
Pikor NB, Prat A, Bar-Or A, Gommerman JL. Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity. Front Immunol. 2016 Jan 13;6(13):657.
Croia C, Serafini B, Bombardieri M, Kelly S, Humby F, Severa M, Rizzo F, Coccia EM, Migliorini P, Aloisi F, Pitzalis C. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 2013 Sep 1;72(9):1559–68.
Cavalcante P, Serafini B, Rosicarelli B, Maggi L, Barberis M, Antozzi C, Berrih-Aknin S, Bernasconi P, Aloisi F, Mantegazza R. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol. 2010 Jun;67(6):726–38.
Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, Piper K, Jonsson R, Tappuni AR, Pitzalis C, Bombardieri M. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren’s syndrome. Arthritis Rheumatol. 2014 Sep;66(9):2545–57.
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004 Apr;14(2):164–74.
Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 2004 Mar 1;148(1):11–23.
Myoung J, Bahk YY, Kang HS, Dal Canto MC, Kim BS. Anticapsid Immunity Level, Not Viral Persistence Level, Correlates with the Progression of Theiler’s Virus-Induced Demyelinating Disease in Viral P1-Transgenic Mice. J Virol. 2008 Jun;82(11):5606–17.
Casiraghi C, Citlali Márquez A, Shanina I, Steven Horwitz M. Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis. Sci Rep. 2015 Sep 10;5:13995.
Jog NR, McClain MT, Heinlen LD, Gross T, Towner R, Guthridge JM, Axtell RC, Pardo G, Harley JB, James JA. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 Jan;106:102332.
Serafini B, Scorsi E, Rosicarelli B, Rigau V, Thouvenot E, Aloisi F. Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal. J Neuroimmunol. 2017 15;307:14–7.
Serafini B, Zandee S, Rosicarelli B, Scorsi E, Veroni C, Larochelle C, D’Alfonso S, Prat A, Aloisi F. Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption. Journal of Neuroimmunology. 2018 Jun 15;319:9–12.
Wong D, Dorovini-Zis K, Vincent SR. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp Neurol. 2004 Dec;190(2):446–55.
Förster C, Burek M, Romero IA, Weksler B, Couraud P-O, Drenckhahn D. Differential effects of hydrocortisone and TNFα on tight junction proteins in an in vitro model of the human blood–brain barrier. J Physiol. 2008 Apr 1;586(Pt 7):1937–49.
TSAO N, HSU HP, WU CM, LIU CC, LEI HYY 2001. Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis. Journal of Medical Microbiology. 50(9):812–21.
Daniels BP, Holman DW, Cruz-Orengo L, Jujjavarapu H, Durrant DM, Klein RS. Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals. mBio. 2014 Aug 26;5(5):e01476-01414.
Chai Q, He WQ, Zhou M, Lu H, Fu ZF. Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J Virol. 2014 May;88(9):4698–710.
Bonney S, Seitz S, Ryan CA, Jones KL, Clarke P, Tyler KL, Siegenthaler JA. Gamma Interferon Alters Junctional Integrity via Rho Kinase, Resulting in Blood-Brain Barrier Leakage in Experimental Viral Encephalitis. mBio. 2019 Aug 6;10(4).
Li F, Wang Y, Yu L, Cao S, Wang K, Yuan J, Wang C, Wang K, Cui M, Fu ZF. Viral Infection of the Central Nervous System and Neuroinflammation Precede Blood-Brain Barrier Disruption during Japanese Encephalitis Virus Infection. J Virol. 2015 May;89(10):5602–14.
Minagar A, Long A, Ma T, Jackson TH, Kelley RE, Ostanin DV, Sasaki M, Warren AC, Jawahar A, Cappell B, Alexander JS. Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium. 2003;10(6):299–307.
Cain MD, Salimi H, Gong Y, Yang L, Hamilton SL, Heffernan JR, Hou J, Miller MJ, Klein RS. Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection. J Neuroimmunol. 2017 Jul 15;308:118–30.
Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight. 2018 Nov 15;3(22):e124714.
Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. J Virol. 2019 15;93(24).

Download PDF

Journal Publication

published 24 Nov, 2021

Read the published version in Frontiers in Immunology →

Version 1

posted

You are reading this latest preprint version

Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Preparation of virus inoculum

Animals and experimental design

Investigating viral spread from the periphery to the CNS

Investigating the dynamics of EBV infection over time

DNA extraction and qPCR for EBV genome

RNA extraction and RT-PCR

Histology, EBER in situ hybridization (EBER-ISH), immunohistochemistry, and immunofluorescence

Protein extraction and ELISA

Statistical analysis

Results

Investigating viral spread from the periphery to the CNS

EBV inoculated rabbits exhibit viremia and high viral DNA load in the periphery

Inflammatory cell aggregates develop in the CNS following peripheral EBV infection

EBV infected cells infiltrate the brain of both immunocompetent and immunosuppressed animals

Investigating the dynamics of EBV infection over time

EBV load peaks at day 14 post infection in peripheral and CNS compartments

The occurrence of CNS aggregates peaks at days 14 and 21 of infection

Peripheral EBV infection results in altered expression of cytokines and latent viral transcripts in the brain

Discussion

Conclusions

Abbreviations

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1